title: Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
authors.affiliation: Vanderbilt University School of Medicine, USA. herbert.meltzer@vanderbilt.edu
authors.forename: Herbert Y
authors.initials: HY
authors.lastname: Meltzer
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine